X0206 3 2020-10-15 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001791249 Ackermann Michael C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 1 0 1 0 Common Stock 1165739 D Series A Preferred Stock Common Stock 53939 D Series B Preferred Stock Common Stock 9246 D Employee Stock Option (right to buy) 2.01 2030-05-13 Common Stock 233605 D Employee Stock Option (right to buy) 10.99 2020-09-24 Common Stock 43114 D The Series A Preferred Stock shall automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series A Preferred Stock has no expiration date. The Series B Preferred Stock shall automatically convert into shares of Common Stock, on a one-for-one basis, immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock has no expiration date. Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). 25% of the option shares will vest and become exercisable on December 13, 2020 and the remainder option shares vest and become exercisable in 36 equal monthly installments thereafter. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020. Exhibit 24 - Power of Attorney /s/ Leo Greenstein, attorney-in-fact 2020-10-15